Sinclair Pharma PLC Silhouette Instalift wins NewBeauty Magazine Award

TIDMSPH

Sinclair Pharma PLC

23 May 2018

FDA CLEARED SILHOUETTE INSTALIFT(R) WINS NEWBEAUTY MAGAZINE BEAUTY CHOICE AWARD

Industry Breakthrough That Has the Power to Change Lives

London, 23 May 2018 Sinclair Pharma plc (AIM:SPH.L) ("Sinclair" or the "Group"), the international aesthetics company, is pleased to announce that its revolutionary facial rejuvenation technology, Silhouette InstaLift (R), has been named a 2018 NewBeauty Magazine Annual Beauty Choice Awards Winner in the category of "Industry Breakthroughs That Have the Power to Change Lives."

The Beauty Choice Awards, announced in the Spring/Summer 2018 issue of NewBeauty Magazine, showcase the "Best Beauty Products and Treatments in the World." Winners are selected by industry experts, NewBeauty editors and readers. Silhouette InstaLift (R) was recognized for its ability to immediately lift and add volume to the midface while maintaining a natural, healthy look and helping to establish and enhance a youthful facial shape, giving patients a more attractive facelift alternative to invasive surgery. Silhouette InstaLift(R) stands among a renowned list of products and treatments to have received this prestigious award.

"My patients don't want to look over-done, so they love Silhouette InstaLift(R) because it helps increase volume while restoring shapeliness to the mid-face and cheek area and still appears natural," said New York Dermatologist, Marina Peredo, MD. "Silhouette InstaLift (R) fulfills a growing need in the explosive skin rejuvenation category and is a game-changing solution for patients who don't want surgery."

"We are honored to earn recognition for our industry-leading treatment from NewBeauty, a publication recognized as a leading resource on aesthetics for consumers and patients," said Mike Zuccala, Vice President, Sales & Marketing, Sinclair USA. "Silhouette InstaLift (R) represents the next generation in non-invasive facial procedures. It is the first and only FDA cleared, minimally invasive procedure that lifts, volumizes, and helps establish a more youthful facial shape with minimal downtime and an excellent safety profile. This award further demonstrates our committment to bringing innovative aesthetic treatments to physicians and their patients."

For further information please contact:

 
 Sinclair Pharma plc   Tel: [phone] 
                        6920 
 Chris Spooner 
 Alan Olby 
 Andy Crane 
 

Media enquiries

 
 FTI Consulting       Tel: [phone] 
                       1000 
 Ben Atwell 
 Brett Pollard 
 Stephanie Cuthbert 
 

Notes to Editors:

About Sinclair Pharma plc - www.sinclairpharma.com

Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. Sinclair is planning entry to multiple new geographic markets and line extension launches over the next few years. The Group has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors.

About Silhouette InstaLift

Silhouette InstaLift is a minimally-invasive, resorbable suspension suture with bi- directional cones. The sutures lift and reposition subdermal tissue while the bi- directional cones hold the suture and facial skin in an elevated position. The suture and cone material are both made of glycolide / L-lactide (PLGA) and over time they stimulate fibroblasts for gradual collagen maturation and are designed to reposition volume in the mid-face with a goal of a natural-looking result.

Connect with us:

Facebook/Twitter/Instagram @InstaliftUS

#SilhouetteInstalift

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward--looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward--looking statements due to a variety of factors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAEASSAAFNPEFF

(END) Dow Jones Newswires

May 23, 2018 03:00 ET (07:00 GMT)